Quantcast
Combining St Johns Wort With Prescription Drugs May Be

Combining St. John's Wort With Prescription Drugs May Be Lethal

Rebekah Eliason for redOrbit.com – Your Universe Online A new study from Wake Forest Baptist Medical Center reports that St. John’s wort, which is the leading complementary and alternative treatment for depression in the United States, is...

Latest Management of depression Stories

2014-06-24 08:29:42

Pharmacogenomic test now available to help guide clinicians' medication decisions for veterans being treated for mental health conditions MASON, Ohio, June 24, 2014 /PRNewswire/ -- Assurex Health today announced that the U.S. Department of Veterans Affairs (VA) has approved its Federal Supply Schedule (FSS) contract as a government supplier, effective June 15, 2014, making the GeneSight(®) Psychotropic test available for use in VA facilities nationwide. The Veterans Health...

depression brain molecule
2014-06-09 04:40:57

redOrbit Staff & Wire Reports - Your Universe Online Levels of a tiny molecule known as miR-1202 are lower in the brains of people suffering from depression, suggesting that it could serve as a marker for depression and help detect which patients are most likely to respond to antidepressant treatment, experts from McGill University and the Douglas Institute claim in a new study. Their research, which has been published by the journal Nature Medicine, shows that miR-1202 could...

2014-06-03 08:31:20

LOS ANGELES, June 03, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) System for the treatment of neurological and neuropsychiatric disorders, today announced that Ian A. Cook, M.D., has joined NeuroSigma on June 1, 2014 as Chief Medical Officer and Senior Vice President. Dr. Cook is a physician and bioengineer who has been an innovator in medical therapeutics and...

2014-05-06 16:32:06

Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK, May 6, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice...

2014-05-06 08:34:13

- Lead NMDA Receptor Modulator GLYX-13 Shows Robust and Sustained Antidepressant Effects with Repeat Dosing and Is Well-Tolerated in Subjects with Difficult-to-Treat Depression - EVANSTON, Ill., May 6, 2014 /PRNewswire/ -- Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones. Top-line results...

2014-05-05 16:26:47

Pilot Study Reveals a Majority of Medication-Free Patients Treated with NeuroStar TMS Experienced Remission After Six Weeks with Durable Effects Through Three Months NEW YORK, May 5, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(®) for Major Depressive Disorder (MDD)....

2014-04-10 08:29:47

BOSTON, April 10, 2014 /PRNewswire/ -- Tal Medical, Inc., a clinical-stage company developing breakthrough treatments for psychiatric diseases, has added two industry veterans to its leadership team. Jan Skvarka has joined as the company's President, CEO and member of the Board of Directors, and Ben Shapiro, MD as a member of the Board of Directors. Jan Skvarka is joining Tal after spending 14 years with Bain and Company, a leading global management consultancy. As one of Bain's...

2014-04-08 23:02:24

Mount Sinai Team Cautiously Optimistic That Door Could Swing Open to A New Antidepressant Drug Class New York, NY (PRWEB) April 08, 2014 A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major depressive disorder. This is the first study to show benefits with an...

2014-04-04 12:14:35

Reducing stress that triggers depression may improve outlook Moderate to severe depression increases the risk of heart failure by 40%, a study of nearly 63 000 Norwegians has shown. The findings were presented for the first time today at EuroHeartCare 2014. EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions (CCNAP) of the European Society of Cardiology (ESC). This year's meeting is organised jointly with the Norwegian Society of...

2014-04-02 23:33:55

New study by researchers Dr. Eric Finzi and Dr. Norman E. Rosenthal published in the Journal of Psychiatric Research May 2014 edition reports that patients injected with onabotulinumtoxinA demonstrated substantial improvement - 52% - in their depressive symptoms. Washington, DC (PRWEB) April 02, 2014 In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (known as Botox) on depression, researchers found that more than half of subjects...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related